Application note: Sensitive detection of viral nucleic acids
A simple and sensitive method for nucleic acid extraction from virus-containing samples, with a range of viral loads.
List view / Grid view
A simple and sensitive method for nucleic acid extraction from virus-containing samples, with a range of viral loads.
Isolate high-quality, inhibitor-free DNA and RNA from human stool and other sample types suitable for metagenomics sequencing.
Learn how fragment-based drug discovery improves hit rates and delivers higher-value targets using various biophysical methods.
Learn why researchers turned to biophysical methods to expose the molecular mechanisms of neurodegenerative diseases.
An antibody called S309, identified in a blood sample from a SARS patient, inhibits related coronaviruses, including SARS-CoV-2, researchers have found.
Scientists have developed a method for designing artificial proteins that tell the immune system which antibodies to produce so could enhance vaccine design.
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
Researchers have made the genome of the Nicotiana benthamiana plant, a commonly used bio-factory organism, public to aid in COVID-19 vaccine production.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
ESHG 2019 Conference Presentation: Using KingFisher™ to increase reproducibility in new applications using challenging samples.
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
A study has revealed that a sponge endemic to an Indonesian bay produces manzamine A, a compound which inhibits proteins in cervical cancers.
Researchers have developed a vaccine against the COVID-19 coronavirus which induced the rapid production of antibodies in mice.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.